A Phase 2 Study of Neratinib with or without Fulvestrant in HER2-Positive ER-Positive Metastatic Breast Cancer

Study Overview

The purpose of this research study is to determine how well neratinib, by itself or together with Fulvestrant, works in treating breast cancer that has spread to other parts of the body. We will also be looking at the side effects associated with this combination of drugs.

Study Description

This is a Phase II study to determine how well neratinib, alone or together with Fulvestrant (FDA approved), works in treating breast cancer that has spread to other parts of the body.

Additional Information

Participants will not be paid for their participation.


  • IRB Number: 1803730353 (17-318)
  • Research Study Identifier: TX8968
  • Principal Investigator: Tarah Ballinger, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176